A wound-healing and hemostatic sponge of squid ink polysaccharide/chitosan, a preparation method and use thereof are provided. The sponge comprises squid ink polysaccharide and chitosan as carriers and calcium chloride as an initiator for blood coagulation, and the wound-healing and hemostatic sponge of squid ink polysaccharide/chitosan is achieved via a lyophilization technology. Particularly, the preparation method comprises slowly adding a squid ink polysaccharide solution to a chitosan solution to form a uniformly mixed solution, adding a calcium chloride solution to the uniformly mixed solution, forming a gel followed by the gel being frozen and then lyophilized, and achieving the product. The wound-healing and hemostatic sponge has a good absorbing-errhysis effect, a good pro-coagulant effect, fast hemostasis and a complete hemostatic effect, without secondary re-hemorrhage. Moreover, the wound-healing and hemostatic sponge can promote wound healing, re-epithelialization and repair of epidermis and dermis, with strong wound-healing ability, good biocompatibility, weak toxic side effects and irritation, belonging to a novel wound-healing and hemostatic material. Moreover, the preparation method is reliable, fast, and low cost.

This document provides methods and materials for treating a mammal (e.g., a human) having one or more tumors. For example, embolic agents including an amnion tissue preparation (e.g., amnion coated embolic agents) that can be used in arterial embolization to reduce or eliminate blood flow in a blood vessel that supplies a tumor are provided.

The present disclosure provides methods of stabilizing surgical screws comprising the intraoperative mixing of reactive putties to yield a homogenous putty composition (HPC) into which the screw is inserted, wherein the HPC comprises a polyurethane or polyurethane urea copolymer, one or more particulate materials, and one or more additive materials.

A cell tissue gel, comprising one or more matrix molecules cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent, wherein the quenching agent contains a moiety that is capable of reacting with the reactive group of the cross-linking agent and the one or more matrix molecules contain one or more functional groups that are capable of cross-linking with the reactive group, the amount of the reactive group of the cross-linking agent being equal to or less than a total amount including the amount of the one or more functional groups and the amount of the moiety.

Provided are synthetic bone graft substitutes that include bioactive glass and a carrier. Synthetic bone graft substitutes may include bioactive glass, glycerol and polyethylene glycol. Also provided are bone graft substitutes that include collagen and bioactive glass particles. Example bone graft substitutes may include collagen and bioactive glass particles. Other example embodiments may include Type I Bovine Collagen, an angiogenic agent, such as hyaluronic acid, and bioactive glass. Further provided are methods that include administering the present bone graft substitutes to a mammal, e.g., by surgical insertion of the bone graft substitute into the mammal, either alone or in conjunction with one or more implant devices. Further provided are kits that include the present bone grafts.

Embolic materials, suspensions, kits and related methods useful for embolization are disclosed. An embolic material can comprise a resorbable microsphere including cross-linked gelatin as its primary ingredient and having a substantially spherical shape with a diameter of about 50 micrometers to about 1,500 micrometers, inclusive. The microsphere can optionally include one or both of a marker or an active agent. The microsphere can be cross-linked, such as with glutaraldehyde or formaldehyde, which can affect the microsphere's in vivo degradation profile and ability to withstand a sterilization process at certain temperatures. In an embodiment, the microspheres can resorb during an in vivo time period of between about 24 hours and about 15 weeks, inclusive. An embolization suspension can include a plurality of resorbable microspheres and a liquid carrier, and the suspension can be disposed in a syringe, vial or other applicator for administration to a patient.

The present invention provides a composition, comprising: proaccelerin (factor V) and at least one factor selected from the group consisting of: prothrombin (factor II), proconvertin (factor VII), and Stuart-Prower factor (factor X), wherein an amount of the proaccelerin in the composition is between 75% to 750% compared to an amount of proaccelerin in a blood plasma, and wherein an amount of the at least one factor is from 150% to 3000% compared to an amount of the at least one factor in the blood plasma; wherein the amount of proaccelerin and the at least one factor in the composition is determined by extrapolating an observed activity of the composition at a concentration of 500 mM NaCl, using a prothrombin complementation assay using a standard curve constructed using the blood plasma.

In some embodiments, the present invention provides compositions including silk fibroin, at least one hydrophilic agent, and at least one catechol donating agent, wherein the at least one hydrophilic agent and at least one catechol donating agent are conjugated to the silk fibroin. According to various embodiments, at least a portion of the silk fibroin may be crosslinked. In some embodiments, the silk fibroin is at least 50% (e.g., 60%, 70%, 80%, 90%, 95% or more) crosslinked. In some embodiments, the present invention also provides methods for making such compositions.

Disclosed herein are methods of connecting disrupted tissue, tissue repair, treating colorectal disorder and tissue welding. The methods comprise using a bioadhesive composition comprising ELP and light absorbing chromophores and irradiating the bioadhesive tissue.

The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell composition preparations for use in tissue regeneration and bone regeneration and pain reduction.